Roivant Executive and Leadership Team

Matthew Gline, the Chief Executive Officer at Roivant, directs the company's overarching strategy and operational execution. Overseeing all business units, Gline ensures alignment with Roivant's mission to deliver innovative healthcare technologies to patients. This leadership position involves guiding the completion of late-stage drug candidate development, a core focus of the company's tech-enabled approach. By driving strategic initiatives, Matthew Gline ensures the efficient allocation of resources across the organization, fostering an environment conducive to scientific advancement and market delivery. The Chief Executive Officer's responsibilities extend to shaping the company's long-term vision and maintaining strong relationships with stakeholders, ultimately impacting the successful delivery of novel therapeutics.

Stephanie Griffin, the Chief Operating Officer, Lysovant at Roivant, spearheads the operational execution and strategic development for Lysovant, a key subsidiary. Overseeing day-to-day operations, Griffin ensures the efficient progression of Lysovant's drug candidates through late-stage development, aligning with Roivant's broader mission. This leadership function involves managing cross-functional teams, optimizing resource allocation, and driving operational excellence within the Lysovant framework. By focusing on operational efficiency, Stephanie Griffin directly contributes to accelerating the delivery of innovative healthcare technologies to patients. The Chief Operating Officer's responsibilities include implementing robust operational strategies that support Lysovant's specific therapeutic focus and market objectives, ensuring seamless integration with Roivant's overall business strategy.

Eric Venker, the President at Roivant, drives strategic initiatives and operational oversight across the organization. Overseeing key business functions, Venker ensures the effective execution of Roivant's mission to complete late-stage drug development and deliver innovative healthcare technologies. This leadership role involves fostering collaboration between different business units and ensuring alignment with the company's overall strategic objectives. By championing operational efficiency and strategic growth, Eric Venker directly contributes to accelerating the delivery of novel therapeutics to patients. The President's responsibilities encompass guiding business development, managing key partnerships, and ensuring the company's continued success in the evolving healthcare landscape.

Ian Rosenblum, the Chief Information Officer at Roivant, architects and manages the company's technology infrastructure and digital strategy. Overseeing all IT operations, Rosenblum ensures the seamless integration of technology to support Roivant's mission of completing late-stage drug development and delivering innovative healthcare solutions. This role is critical in leveraging data analytics and digital tools to accelerate R&D processes and enhance patient access to novel treatments. By driving technological innovation, Ian Rosenblum supports the operational efficiency of the entire organization, enabling faster decision-making and improved collaboration across teams. The Chief Information Officer's focus includes cybersecurity, data management, and the implementation of advanced platforms that underpin Roivant's tech-enabled healthcare model.

Deya Corzo, the Chief Medical Officer, -Residence at Roivant, provides critical medical and scientific leadership, guiding the clinical development of promising drug candidates. Overseeing the medical strategy, Corzo ensures that clinical trials and research initiatives align with regulatory requirements and patient needs, supporting Roivant's commitment to delivering innovative healthcare. This role is pivotal in translating scientific insights into tangible patient benefits, driving the completion of late-stage development programs. By directing medical affairs, Deya Corzo ensures the scientific integrity and efficacy of Roivant's therapeutic pipeline. The Chief Medical Officer's expertise is essential in navigating complex clinical landscapes and advancing healthcare technologies from development to patient access.